{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:11:26Z","timestamp":1790759486460,"version":"4.1.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071101"],"award-info":[{"award-number":["82071101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515010949"],"award-info":[{"award-number":["2021A1515010949"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013153","name":"Shantou Science and Technology Project","doi-asserted-by":"publisher","award":["200624095260243"],"award-info":[{"award-number":["200624095260243"]}],"id":[{"id":"10.13039\/501100013153","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite advances in therapeutic strategies, resistance to immunotherapy and the off-target effects of targeted therapy have significantly weakened the benefits for patients with melanoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Alternative splicing plays a crucial role in transcriptional reprogramming during melanoma development. In particular, aberrant alternative splicing is involved in the efficacy of immunotherapy, targeted therapy, and melanoma metastasis. Abnormal expression of splicing factors and variants may serve as biomarkers or therapeutic targets for the diagnosis and prognosis of melanoma. Therefore, comprehensively integrating their roles and related mechanisms is essential. This review provides the first detailed summary of the splicing process in melanoma and the changes occurring in this pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The focus of this review is to provide strategies for developing novel diagnostic biomarkers and summarize their potential to alter resistance to targeted therapies and immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-024-03280-x","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T14:01:17Z","timestamp":1710079277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Roles and mechanisms of aberrant alternative splicing in melanoma \u2014 implications for targeted therapy and immunotherapy resistance"],"prefix":"10.1186","volume":"24","author":[{"given":"Wanxian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosha","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genghong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,10]]},"reference":[{"issue":"9919","key":"3280_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","volume":"383","author":"AM Eggermont","year":"2014","unstructured":"Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014;383(9919):816\u201327.","journal-title":"Lancet"},{"issue":"6","key":"3280_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ccr.2005.11.008","volume":"8","author":"O Kabbarah","year":"2005","unstructured":"Kabbarah O, Chin L. Revealing the genomic heterogeneity of melanoma. Cancer Cell. 2005;8(6):439\u201341.","journal-title":"Cancer Cell"},{"issue":"2","key":"3280_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251\u201363.","journal-title":"Cell"},{"issue":"4","key":"3280_CR4","first-page":"1071","volume":"52","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Falzone L, Salemi R, Zangh\u00ec A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (review). Int J Oncol. 2018;52(4):1071\u201380.","journal-title":"Int J Oncol"},{"issue":"7","key":"3280_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626\u201336.","journal-title":"N Engl J Med"},{"issue":"4","key":"3280_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"3280_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2010.09.007","volume":"20","author":"PV Dickson","year":"2011","unstructured":"Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1\u201317.","journal-title":"Surg Oncol Clin N Am"},{"issue":"7","key":"3280_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","volume":"19","author":"I Arozarena","year":"2019","unstructured":"Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19(7):377\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3280_CR9","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/0008-5472.CAN-18-2762","volume":"79","author":"L Benito-Jard\u00f3n","year":"2019","unstructured":"Benito-Jard\u00f3n L, D\u00edaz-Mart\u00ednez M, Arellano-S\u00e1nchez N, Vaquero-Morales P, Espar\u00eds-Ogando A, Teixid\u00f3 J. Resistance to MAPK inhibitors in Melanoma involves activation of the IGF1R-MEK5-Erk5 pathway. Cancer Res. 2019;79(9):2244\u201356.","journal-title":"Cancer Res"},{"issue":"1","key":"3280_CR10","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","volume":"11","author":"JH Lee","year":"2020","unstructured":"Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, et al. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat Commun. 2020;11(1):1897.","journal-title":"Nat Commun"},{"issue":"2","key":"3280_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles A, Lehmann KV, Toussaint NC, H\u00fcser M, Stark SG, Sachsenberg T, et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 patients. Cancer Cell. 2018;34(2):211\u2013224e6.","journal-title":"Cancer Cell"},{"issue":"3","key":"3280_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczuk\u00f3w O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23(3):135\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"3280_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrc.2016.51","volume":"16","author":"H Dvinge","year":"2016","unstructured":"Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16(7):413\u201330.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3280_CR14","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/ijms21051551","volume":"21","author":"T Takeiwa","year":"2020","unstructured":"Takeiwa T, Mitobe Y, Ikeda K, Horie-Inoue K, Inoue S. Roles of splicing factors in hormone-related Cancer Progression. Int J Mol Sci. 2020;21(5):1551.","journal-title":"Int J Mol Sci"},{"key":"3280_CR15","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.drup.2020.100728","volume":"53","author":"R Sciarrillo","year":"2020","unstructured":"Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updat. 2020;53:100728.","journal-title":"Drug Resist Updat"},{"issue":"7","key":"3280_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41587-022-01224-2","volume":"40","author":"K North","year":"2022","unstructured":"North K, Benbarche S, Liu B, Pangallo J, Chen S, Stahl M, et al. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nat Biotechnol. 2022;40(7):1103\u201313.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"3280_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal SC, L\u00f3pez-Oreja I, Valc\u00e1rcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17(8):457\u201374.","journal-title":"Nat Rev Clin Oncol"},{"key":"3280_CR18","unstructured":"mRNA splicing variants. : exploiting modularity to outwit cancer therapy - PubMed [Internet]. [cited 2023 May 14]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23970479\/."},{"issue":"6","key":"3280_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1101\/gr.199935.115","volume":"26","author":"E Sebesty\u00e9n","year":"2016","unstructured":"Sebesty\u00e9n E, Singh B, Mi\u00f1ana B, Pag\u00e8s A, Mateo F, Pujana MA, et al. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res. 2016;26(6):732\u201344.","journal-title":"Genome Res"},{"issue":"11","key":"3280_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41576-019-0150-2","volume":"20","author":"R Stark","year":"2019","unstructured":"Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet. 2019;20(11):631\u201356.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"3280_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrm.2017.27","volume":"18","author":"FE Baralle","year":"2017","unstructured":"Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18(7):437\u201351.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"3280_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2017.04.033","volume":"169","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yan C, Hang J, Finci LI, Lei J, Shi Y. An atomic structure of the human spliceosome. Cell. 2017;169(5):918\u2013929e14.","journal-title":"Cell"},{"issue":"9","key":"3280_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1261\/rna.057919.116","volume":"22","author":"O Anczuk\u00f3w","year":"2016","unstructured":"Anczuk\u00f3w O, Krainer AR. Splicing-factor alterations in cancers. RNA. 2016;22(9):1285\u2013301.","journal-title":"RNA"},{"issue":"9","key":"3280_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1017\/S1355838200000960","volume":"6","author":"BR Graveley","year":"2000","unstructured":"Graveley BR. Sorting out the complexity of SR protein functions. RNA. 2000;6(9):1197\u2013211.","journal-title":"RNA"},{"issue":"10","key":"3280_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrg3778","volume":"15","author":"XD Fu","year":"2014","unstructured":"Fu XD, Ares M. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet. 2014;15(10):689\u2013701.","journal-title":"Nat Rev Genet"},{"key":"3280_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2014.03.011","volume":"32","author":"ML \u00c4nk\u00f6","year":"2014","unstructured":"\u00c4nk\u00f6 ML. Regulation of gene expression programmes by serine-arginine rich splicing factors. Semin Cell Dev Biol. 2014;32:11\u201321.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"3280_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BJ20081501","volume":"417","author":"JC Long","year":"2009","unstructured":"Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 2009;417(1):15\u201327.","journal-title":"Biochem J"},{"issue":"1","key":"3280_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wrna.100","volume":"3","author":"A Busch","year":"2012","unstructured":"Busch A, Hertel KJ. Evolution of SR protein and hnRNP splicing regulatory factors. Wiley Interdiscip Rev RNA. 2012;3(1):1\u201312.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"10","key":"3280_CR29","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1017\/S1355838202028030","volume":"8","author":"BJ Lam","year":"2002","unstructured":"Lam BJ, Hertel KJ. A general role for splicing enhancers in exon definition. RNA. 2002;8(10):1233\u201341.","journal-title":"RNA"},{"issue":"1","key":"3280_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12013-019-00895-0","volume":"78","author":"C Jin","year":"2020","unstructured":"Jin C, Dong D, Yang Z, Xia R, Tao S, Piao M. CircMYC regulates glycolysis and cell proliferation in Melanoma. Cell Biochem Biophys. 2020;78(1):77\u201388.","journal-title":"Cell Biochem Biophys"},{"issue":"3","key":"3280_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/bjc.2014.342","volume":"111","author":"MV Gammons","year":"2014","unstructured":"Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014;111(3):477\u201385.","journal-title":"Br J Cancer"},{"key":"3280_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.taap.2018.08.012","volume":"356","author":"GA Moreira","year":"2018","unstructured":"Moreira GA, Lima GD, de Siqueira A, Barros RP, de Adjanohoun MV, Santos ALM. Antimetastatic effect of the pharmacological inhibition of serine\/arginine-rich protein kinases (SRPK) in murine melanoma. Toxicol Appl Pharmacol. 2018;356:214\u201323.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3280_CR33","doi-asserted-by":"publisher","first-page":"979735","DOI":"10.3389\/fgene.2022.979735","volume":"13","author":"MMM Caetano","year":"2022","unstructured":"Caetano MMM, Moreira GA, da Silva MR, Guimar\u00e3es GR, Santos L, de de O, Pacheco A. Impaired expression of serine\/arginine protein kinase 2 (SRPK2) affects melanoma progression. Front Genet. 2022;13:979735.","journal-title":"Front Genet"},{"key":"3280_CR34","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.bcp.2022.115161","volume":"203","author":"GA Moreira","year":"2022","unstructured":"Moreira GA, Caetano MMM, do Vale JA, de Paiva JC, Gon\u00e7alves VHS, Almeida AA, et al. The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice. Biochem Pharmacol. 2022;203:115161.","journal-title":"Biochem Pharmacol"},{"issue":"22","key":"3280_CR35","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1038\/onc.2012.288","volume":"32","author":"Y Tang","year":"2013","unstructured":"Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, et al. Downregulation of splicing factor SRSF3 induces p53\u03b2, an alternatively spliced isoform of p53 that promotes cellular senescence. Oncogene. 2013;32(22):2792\u20138.","journal-title":"Oncogene"},{"issue":"1","key":"3280_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2013.05.027","volume":"436","author":"C Corbo","year":"2013","unstructured":"Corbo C, Orr\u00f9 S, Salvatore F. SRp20: an overview of its role in human diseases. Biochem Biophys Res Commun. 2013;436(1):1\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"3280_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1172\/JCI82534","volume":"126","author":"M Dewaele","year":"2016","unstructured":"Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DHP, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016;126(1):68\u201384.","journal-title":"J Clin Invest"},{"issue":"9","key":"3280_CR38","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1038\/cddis.2010.48","volume":"1","author":"CC Jiang","year":"2010","unstructured":"Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM, et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 2010;1(9):e69.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3280_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/CMR.0b013e328353eff2","volume":"22","author":"F Lai","year":"2012","unstructured":"Lai F, Jiang CC, Farrelly ML, Zhang XD, Hersey P. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Res. 2012;22(3):244\u201351.","journal-title":"Melanoma Res"},{"issue":"8","key":"3280_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00439-016-1683-5","volume":"135","author":"T Geuens","year":"2016","unstructured":"Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet. 2016;135(8):851\u201367.","journal-title":"Hum Genet"},{"key":"3280_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.bi.62.070193.001445","volume":"62","author":"G Dreyfuss","year":"1993","unstructured":"Dreyfuss G, Matunis MJ, Pi\u00f1ol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993;62:289\u2013321.","journal-title":"Annu Rev Biochem"},{"issue":"13","key":"3280_CR42","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1158\/0008-5472.CAN-10-4410","volume":"71","author":"R Golan-Gerstl","year":"2011","unstructured":"Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bak\u00e0cs A, Coppola L, et al. Splicing factor hnRNP A2\/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 2011;71(13):4464\u201372.","journal-title":"Cancer Res"},{"issue":"5","key":"3280_CR43","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1073\/pnas.0914845107","volume":"107","author":"CV Clower","year":"2010","unstructured":"Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR. The alternative splicing repressors hnRNP A1\/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010;107(5):1894\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3280_CR44","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cmet.2013.04.013","volume":"17","author":"I Babic","year":"2013","unstructured":"Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013;17(6):1000\u20138.","journal-title":"Cell Metab"},{"issue":"7279","key":"3280_CR45","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nature08697","volume":"463","author":"CJ David","year":"2010","unstructured":"David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463(7279):364\u20138.","journal-title":"Nature"},{"key":"3280_CR46","unstructured":"Sl YL. S. The roles of hnRNP A2\/B1 in RNA biology and disease. Wiley interdisciplinary reviews RNA [Internet]. 2021 Mar [cited 2023 May 14];12(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32588964\/."},{"issue":"1","key":"3280_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13304","volume":"163","author":"G Geng","year":"2021","unstructured":"Geng G, Xu C, Peng N, Li Y, Liu J, Wu J, et al. PTBP1 is necessary for dendritic cells to regulate T-cell homeostasis and antitumour immunity. Immunology. 2021;163(1):74\u201385.","journal-title":"Immunology"},{"issue":"52","key":"3280_CR48","doi-asserted-by":"publisher","first-page":"e32428","DOI":"10.1097\/MD.0000000000032428","volume":"101","author":"Q Huang","year":"2022","unstructured":"Huang Q, Gu S, Fang J, Li X, Lin L. A pan-cancer analysis of the oncogenic role of polypyrimidine tract binding protein 1 (PTBP1) in human tumors. Med (Baltim). 2022;101(52):e32428.","journal-title":"Med (Baltim)"},{"issue":"5","key":"3280_CR49","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3390\/ijms23052704","volume":"23","author":"A Lad\u00e1nyi","year":"2022","unstructured":"Lad\u00e1nyi A, R\u00e1s\u00f3 E, Barbai T, V\u00edzkeleti L, Pusk\u00e1s LG, Kov\u00e1cs SA, et al. Identification of a Tumor Cell Associated Type I IFN Resistance Gene expression signature of human melanoma, the components of which have a predictive potential for Immunotherapy. Int J Mol Sci. 2022;23(5):2704.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3280_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/pcmr.12307","volume":"28","author":"DM Marzese","year":"2015","unstructured":"Marzese DM, Liu M, Huynh JL, Hirose H, Donovan NC, Huynh KT, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82\u201393.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"3280_CR51","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/1878-0261.13088","volume":"16","author":"M Charpentier","year":"2022","unstructured":"Charpentier M, Dupr\u00e9 E, Fortun A, Briand F, Maillasson M, Com E, et al. hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cells. Mol Oncol. 2022;16(3):594\u2013606.","journal-title":"Mol Oncol"},{"issue":"1","key":"3280_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13287-020-02124-5","volume":"12","author":"M Chu","year":"2021","unstructured":"Chu M, Wan H, Zhang X. Requirement of splicing factor hnRNP A2B1 for tumorigenesis of melanoma stem cells. Stem Cell Res Ther. 2021;12(1):90.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"3280_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-022-00366-4","volume":"10","author":"L Mo","year":"2022","unstructured":"Mo L, Meng L, Huang Z, Yi L, Yang N, Li G. An analysis of the role of HnRNP C dysregulation in cancers. Biomark Res. 2022;10(1):19.","journal-title":"Biomark Res"},{"issue":"1","key":"3280_CR54","doi-asserted-by":"publisher","first-page":"BSR20181312","DOI":"10.1042\/BSR20181312","volume":"39","author":"LL Coa","year":"2019","unstructured":"Coa LL, Abreu TF, Tashima AK, Green J, Pascon RC, Vallim MA, et al. AKT\/protein kinase B associates with \u03b2-actin in the nucleus of melanoma cells. Biosci Rep. 2019;39(1):BSR20181312.","journal-title":"Biosci Rep"},{"issue":"2","key":"3280_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","volume":"64","author":"C Cretu","year":"2016","unstructured":"Cretu C, Schmitzov\u00e1 J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular Architecture of SF3b and Structural consequences of its Cancer-related mutations. Mol Cell. 2016;64(2):307\u201319.","journal-title":"Mol Cell"},{"issue":"18","key":"3280_CR56","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1093\/emboj\/cdf480","volume":"21","author":"CL Will","year":"2002","unstructured":"Will CL, Urlaub H, Achsel T, Gentzel M, Wilm M, L\u00fchrmann R. Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J. 2002;21(18):4978\u201388.","journal-title":"EMBO J"},{"issue":"3","key":"3280_CR57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ccell.2016.08.013","volume":"30","author":"D Inoue","year":"2016","unstructured":"Inoue D, Abdel-Wahab O. Modeling SF3B1 mutations in Cancer: advances, challenges, and opportunities. Cancer Cell. 2016;30(3):371\u20133.","journal-title":"Cancer Cell"},{"issue":"19","key":"3280_CR58","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1002\/cncr.33745","volume":"127","author":"R Kanagal-Shamanna","year":"2021","unstructured":"Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, et al. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021;127(19):3552\u201365.","journal-title":"Cancer"},{"issue":"2","key":"3280_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45(2):133\u20135.","journal-title":"Nat Genet"},{"issue":"4","key":"3280_CR60","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CMR.0000000000000071","volume":"24","author":"Y Kong","year":"2014","unstructured":"Kong Y, Krauthammer M, Halaban R. Rare SF3B1 R625 mutations in cutaneous melanoma. Melanoma Res. 2014;24(4):332\u20134.","journal-title":"Melanoma Res"},{"issue":"24","key":"3280_CR61","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.3390\/ijms21249546","volume":"21","author":"JQN Nguyen","year":"2020","unstructured":"Nguyen JQN, Drabarek W, Yavuzyigitoglu S, Medico Salsench E, Verdijk RM, Naus NC, et al. Spliceosome mutations in Uveal Melanoma. Int J Mol Sci. 2020;21(24):9546.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3280_CR62","doi-asserted-by":"publisher","first-page":"e138315","DOI":"10.1172\/JCI138315","volume":"131","author":"B Liu","year":"2021","unstructured":"Liu B, Liu Z, Chen S, Ki M, Erickson C, Reis-Filho JS, et al. Mutant SF3B1 promotes AKT- and NF-\u03baB-driven mammary tumorigenesis. J Clin Invest. 2021;131(1):e138315.","journal-title":"J Clin Invest"},{"issue":"3","key":"3280_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/ICU.0000000000000051","volume":"25","author":"MG Field","year":"2014","unstructured":"Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234\u20139.","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"3280_CR64","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1158\/2159-8290.CD-20-0555","volume":"11","author":"J Bigot","year":"2021","unstructured":"Bigot J, Lalanne AI, Lucibello F, Gueguen P, Houy A, Dayot S, et al. Splicing patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021;11(8):1938\u201351.","journal-title":"Cancer Discov"},{"issue":"10","key":"3280_CR65","doi-asserted-by":"publisher","first-page":"e0205491","DOI":"10.1371\/journal.pone.0205491","volume":"13","author":"J Harper","year":"2018","unstructured":"Harper J, Adams KJ, Bossi G, Wright DE, Stacey AR, Bedke N, et al. An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS ONE. 2018;13(10):e0205491.","journal-title":"PLoS ONE"},{"issue":"6","key":"3280_CR66","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nm.2764","volume":"18","author":"N Liddy","year":"2012","unstructured":"Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012;18(6):980\u20137.","journal-title":"Nat Med"},{"issue":"7928","key":"3280_CR67","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41586-022-05204-z","volume":"609","author":"M Hluch\u00fd","year":"2022","unstructured":"Hluch\u00fd M, Gajdu\u0161kov\u00e1 P, Ruiz de Los Mozos I, R\u00e1jeck\u00fd M, Kluge M, Berger BT, et al. CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. Nature. 2022;609(7928):829\u201334.","journal-title":"Nature"},{"issue":"80","key":"3280_CR68","doi-asserted-by":"publisher","first-page":"eabm6360","DOI":"10.1126\/sciimmunol.abm6360","volume":"8","author":"M Burbage","year":"2023","unstructured":"Burbage M, Roca\u00f1\u00edn-Arj\u00f3 A, Baudon B, Arribas YA, Merlotti A, Rookhuizen DC, et al. Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements. Sci Immunol. 2023;8(80):eabm6360.","journal-title":"Sci Immunol"},{"issue":"4","key":"3280_CR69","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s12276-020-0429-6","volume":"52","author":"HD Yang","year":"2020","unstructured":"Yang HD, Nam SW. Pathogenic diversity of RNA variants and RNA variation-associated factors in cancer development. Exp Mol Med. 2020;52(4):582\u201393.","journal-title":"Exp Mol Med"},{"issue":"1","key":"3280_CR70","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-021-21457-0","volume":"12","author":"WM Song","year":"2021","unstructured":"Song WM, Agrawal P, Von Itter R, Fontanals-Cirera B, Wang M, Zhou X, et al. Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis. Nat Commun. 2021;12(1):1214.","journal-title":"Nat Commun"},{"issue":"4","key":"3280_CR71","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1042\/BST20140020","volume":"42","author":"C Wellbrock","year":"2014","unstructured":"Wellbrock C. MAPK pathway inhibition in melanoma: resistance three ways. Biochem Soc Trans. 2014;42(4):727\u201332.","journal-title":"Biochem Soc Trans"},{"issue":"7693","key":"3280_CR72","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature25478","volume":"554","author":"H Lavoie","year":"2018","unstructured":"Lavoie H, Sahmi M, Maisonneuve P, Marullo SA, Thevakumaran N, Jin T, et al. MEK drives BRAF activation through allosteric control of KSR proteins. Nature. 2018;554(7693):549\u201353.","journal-title":"Nature"},{"key":"3280_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-017-0098-3","volume":"5","author":"GM Pupo","year":"2017","unstructured":"Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, et al. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomark Res. 2017;5:17.","journal-title":"Biomark Res"},{"issue":"6892","key":"3280_CR74","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"key":"3280_CR75","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","volume":"135","author":"R Roskoski","year":"2018","unstructured":"Roskoski R. Targeting oncogenic raf protein-serine\/threonine kinases in human cancers. Pharmacol Res. 2018;135:239\u201358.","journal-title":"Pharmacol Res"},{"issue":"7377","key":"3280_CR76","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387\u201390.","journal-title":"Nature"},{"key":"3280_CR77","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1038\/ncomms8103","volume":"6","author":"M Salton","year":"2015","unstructured":"Salton M, Kasprzak WK, Voss T, Shapiro BA, Poulikakos PI, Misteli T. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun. 2015;6:7103.","journal-title":"Nat Commun"},{"issue":"1","key":"3280_CR78","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1535-7163.MCT-17-0705","volume":"17","author":"EJ Hartsough","year":"2018","unstructured":"Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, et al. Response and resistance to Paradox-breaking BRAF inhibitor in Melanomas in vivo and Ex vivo. Mol Cancer Ther. 2018;17(1):84\u201395.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3280_CR79","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/pcmr.12218","volume":"27","author":"KJ Basile","year":"2014","unstructured":"Basile KJ, Le K, Hartsough EJ, Aplin AE. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014;27(3):479\u201384.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"3280_CR80","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1128\/MCB.18.7.3947","volume":"18","author":"S Roy","year":"1998","unstructured":"Roy S, McPherson RA, Apolloni A, Yan J, Lane A, Clyde-Smith J, et al. 14-3-3 facilitates ras-dependent Raf-1 activation in vitro and in vivo. Mol Cell Biol. 1998;18(7):3947\u201355.","journal-title":"Mol Cell Biol"},{"issue":"14","key":"3280_CR81","doi-asserted-by":"publisher","first-page":"14074","DOI":"10.1074\/jbc.M309620200","volume":"279","author":"M Hekman","year":"2004","unstructured":"Hekman M, Wiese S, Metz R, Albert S, Troppmair J, Nickel J, et al. Dynamic changes in C-Raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation: differential roles of 14-3-3 protein binding sites. J Biol Chem. 2004;279(14):14074\u201386.","journal-title":"J Biol Chem"},{"issue":"1","key":"3280_CR82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1128\/MCB.01265-06","volume":"27","author":"I Hmitou","year":"2007","unstructured":"Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eych\u00e8ne A. Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol. 2007;27(1):31\u201343.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"3280_CR83","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1128\/MCB.00569-09","volume":"30","author":"DA Ritt","year":"2010","unstructured":"Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol. 2010;30(3):806\u201319.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"3280_CR84","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF mutants evade ERK-Dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell. 2015;28(3):370\u201383.","journal-title":"Cancer Cell"},{"issue":"7783","key":"3280_CR85","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41586-019-1660-y","volume":"575","author":"E Park","year":"2019","unstructured":"Park E, Rawson S, Li K, Kim BW, Ficarro SB, Pino GGD, et al. Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes. Nature. 2019;575(7783):545\u201350.","journal-title":"Nature"},{"issue":"4","key":"3280_CR86","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/pcmr.12932","volume":"34","author":"MJ Vido","year":"2021","unstructured":"Vido MJ, Rock J, Aplin AE. Role of serine 365 in BRAF V600E sensitivity to RAF inhibition. Pigment Cell Melanoma Res. 2021;34(4):696\u2013702.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"3280_CR87","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mrd.1080420419","volume":"42","author":"F McCormick","year":"1995","unstructured":"McCormick F. Ras-related proteins in signal transduction and growth control. Mol Reprod Dev. 1995;42(4):500\u20136.","journal-title":"Mol Reprod Dev"},{"issue":"16","key":"3280_CR88","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014\u201323.","journal-title":"Cancer"},{"issue":"10","key":"3280_CR89","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/nm.2941","volume":"18","author":"LN Kwong","year":"2012","unstructured":"Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18(10):1503\u201310.","journal-title":"Nat Med"},{"issue":"12","key":"3280_CR90","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30(12):1884\u2013901.","journal-title":"Ann Oncol"},{"issue":"3","key":"3280_CR91","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/cancers13030475","volume":"13","author":"M Guida","year":"2021","unstructured":"Guida M, Bartolomeo N, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, et al. No impact of NRAS Mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: an Italian Melanoma Intergroup (IMI) Study. Cancers (Basel). 2021;13(3):475.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3280_CR92","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","volume":"1","author":"NE Thomas","year":"2015","unstructured":"Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, et al. Association between NRAS and BRAF Mutational Status and Melanoma-Specific Survival among patients with higher-risk primary melanoma. JAMA Oncol. 2015;1(3):359\u201368.","journal-title":"JAMA Oncol"},{"issue":"4","key":"3280_CR93","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435\u201345.","journal-title":"Lancet Oncol"},{"key":"3280_CR94","doi-asserted-by":"publisher","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","volume":"99","author":"T Randic","year":"2021","unstructured":"Randic T, Kozar I, Margue C, Utikal J, Kreis S. NRAS mutant melanoma: towards better therapies. Cancer Treat Rev. 2021;99:102238.","journal-title":"Cancer Treat Rev"},{"key":"3280_CR95","doi-asserted-by":"crossref","unstructured":"Ak E, Kw SS, Cj H. W, S L, R P, NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2014 Mar 18 [cited 2023 May 15];111(11). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24586049\/.","DOI":"10.1073\/pnas.1401727111"},{"issue":"12","key":"3280_CR96","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/2159-8290.CD-14-0729","volume":"4","author":"CE Burd","year":"2014","unstructured":"Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014;4(12):1418\u201329.","journal-title":"Cancer Discov"},{"key":"3280_CR97","unstructured":"Identification of NRAS isoform. 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma - PubMed [Internet]. [cited 2023 May 15]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28827320\/."},{"issue":"5","key":"3280_CR98","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/pro.2916","volume":"25","author":"J Markowitz","year":"2016","unstructured":"Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, et al. Structural characterization of NRAS isoform 5. Protein Sci. 2016;25(5):1069\u201374.","journal-title":"Protein Sci"},{"issue":"5","key":"3280_CR99","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/CMR.0000000000000623","volume":"29","author":"MC Duggan","year":"2019","unstructured":"Duggan MC, Regan-Fendt K, Olaverria Salavaggione GN, Howard JH, Stiff AR, Sabella J, et al. Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy. Melanoma Res. 2019;29(5):491\u2013500.","journal-title":"Melanoma Res"},{"issue":"4","key":"3280_CR100","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10555-020-09920-8","volume":"39","author":"E R\u00e1s\u00f3","year":"2020","unstructured":"R\u00e1s\u00f3 E. Splice variants of RAS-translational significance. Cancer Metastasis Rev. 2020;39(4):1039\u201349.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"3280_CR101","doi-asserted-by":"publisher","first-page":"494","DOI":"10.18632\/oncotarget.970","volume":"4","author":"C Posch","year":"2013","unstructured":"Posch C, Ortiz-Urda S. NRAS mutant melanoma\u2013undrugable? Oncotarget. 2013;4(4):494\u20135.","journal-title":"Oncotarget"},{"issue":"2","key":"3280_CR102","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.critrevonc.2014.05.005","volume":"92","author":"M Mandal\u00e0","year":"2014","unstructured":"Mandal\u00e0 M, Merelli B, Massi D. Nras in melanoma: targeting the undruggable target. Crit Rev Oncol Hematol. 2014;92(2):107\u201322.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3280_CR103","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"3280_CR104","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2174\/138920208785699571","volume":"9","author":"J Eberle","year":"2008","unstructured":"Eberle J, Hossini AM. Expression and function of bcl-2 proteins in melanoma. Curr Genomics. 2008;9(6):409\u201319.","journal-title":"Curr Genomics"},{"issue":"1","key":"3280_CR105","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25(1):65\u201380.","journal-title":"Cell Death Differ"},{"issue":"25","key":"3280_CR106","doi-asserted-by":"publisher","first-page":"19615","DOI":"10.1074\/jbc.M110.105452","volume":"285","author":"Q Liu","year":"2010","unstructured":"Liu Q, Moldoveanu T, Sprules T, Matta-Camacho E, Mansur-Azzam N, Gehring K. Apoptotic regulation by MCL-1 through heterodimerization. J Biol Chem. 2010;285(25):19615\u201324.","journal-title":"J Biol Chem"},{"issue":"4","key":"3280_CR107","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/cr.2010.149","volume":"21","author":"B Ku","year":"2011","unstructured":"Ku B, Liang C, Jung JU, Oh BH. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 2011;21(4):627\u201341.","journal-title":"Cell Res"},{"issue":"3","key":"3280_CR108","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.cell.2012.12.031","volume":"152","author":"PE Czabotar","year":"2013","unstructured":"Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD, et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell. 2013;152(3):519\u201331.","journal-title":"Cell"},{"issue":"5","key":"3280_CR109","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nsmb.2563","volume":"20","author":"T Moldoveanu","year":"2013","unstructured":"Moldoveanu T, Grace CR, Llambi F, Nourse A, Fitzgerald P, Gehring K, et al. BID-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol. 2013;20(5):589\u201397.","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"3280_CR110","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3390\/ijms22052777","volume":"22","author":"AM Lucian\u00f2","year":"2021","unstructured":"Lucian\u00f2 AM, P\u00e9rez-Oliva AB, Mulero V, Del Bufalo D. Bcl-xL: a focus on Melanoma Pathobiology. Int J Mol Sci. 2021;22(5):2777.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3280_CR111","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/ijms19010308","volume":"19","author":"J Cui","year":"2018","unstructured":"Cui J, Placzek WJ. Post-transcriptional regulation of anti-apoptotic BCL2 family members. Int J Mol Sci. 2018;19(1):308.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3280_CR112","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2010.07.019","volume":"142","author":"MJ Moore","year":"2010","unstructured":"Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell. 2010;142(4):625\u201336.","journal-title":"Cell"},{"issue":"11","key":"3280_CR113","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/exd.12254","volume":"22","author":"CS McKee","year":"2013","unstructured":"McKee CS, Hill DS, Redfern CPF, Armstrong JL, Lovat PE. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma. Exp Dermatol. 2013;22(11):767\u20139.","journal-title":"Exp Dermatol"},{"issue":"8","key":"3280_CR114","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/ijc.33000","volume":"147","author":"HY Tseng","year":"2020","unstructured":"Tseng HY, Dreyer J, Emran AA, Gunatilake D, Pirozyan M, Cullinane C, et al. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. Int J Cancer. 2020;147(8):2176\u201389.","journal-title":"Int J Cancer"},{"issue":"1","key":"3280_CR115","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41467-018-08150-5","volume":"10","author":"D Aird","year":"2019","unstructured":"Aird D, Teng T, Huang CL, Pazolli E, Banka D, Cheung-Ong K, et al. Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. Nat Commun. 2019;10(1):137.","journal-title":"Nat Commun"},{"issue":"1","key":"3280_CR116","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1038\/s41467-019-12409-w","volume":"10","author":"MJ Sale","year":"2019","unstructured":"Sale MJ, Minihane E, Monks NR, Gilley R, Richards FM, Schifferli KP, et al. Targeting melanoma\u2019s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1\/2 pathway inhibitors. Nat Commun. 2019;10(1):5167.","journal-title":"Nat Commun"},{"issue":"3","key":"3280_CR117","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.bbrc.2005.03.151","volume":"331","author":"JC Marine","year":"2005","unstructured":"Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun. 2005;331(3):750\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"3280_CR118","unstructured":"D D, E M, D P, D M, M C, R F, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Molecular and cellular biology [Internet]. 2004 Jul [cited 2023 May 15];24(13). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15199139\/."},{"key":"3280_CR119","doi-asserted-by":"crossref","unstructured":"Gm FT. W. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature reviews Cancer [Internet]. 2006 Dec [cited 2023 May 15];6(12). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17128209\/.","DOI":"10.1038\/nrc2012"},{"key":"3280_CR120","doi-asserted-by":"crossref","unstructured":"Yc MW, Gm L. W. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature reviews Cancer [Internet]. 2013 Feb [cited 2023 May 15];13(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23303139\/.","DOI":"10.1038\/nrc3430"},{"key":"3280_CR121","unstructured":"Jc M. MDM2 and MDMX in cancer and development. Current topics in developmental biology [Internet]. 2011 [cited 2023 May 15];94. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21295684\/."},{"issue":"1","key":"3280_CR122","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1101\/gad.247361.114","volume":"29","author":"PL Boutz","year":"2015","unstructured":"Boutz PL, Bhutkar A, Sharp PA. Detained introns are a novel, widespread class of post-transcriptionally spliced introns. Genes Dev. 2015;29(1):63\u201380.","journal-title":"Genes Dev"},{"issue":"3","key":"3280_CR123","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00412-013-0407-z","volume":"122","author":"Z Zhou","year":"2013","unstructured":"Zhou Z, Fu XD. Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma. 2013;122(3):191\u2013207.","journal-title":"Chromosoma"},{"issue":"36","key":"3280_CR124","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1073\/pnas.1901323116","volume":"116","author":"S AbuHammad","year":"2019","unstructured":"AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma. Proc Natl Acad Sci U S A. 2019;116(36):17990\u20138000.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"3280_CR125","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4161\/cc.21195","volume":"11","author":"JL Dean","year":"2012","unstructured":"Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, et al. Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012;11(14):2756\u201361.","journal-title":"Cell Cycle"},{"issue":"8","key":"3280_CR126","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early Adaptation and Acquired Resistance to CDK4\/6 inhibition in Estrogen receptor-positive breast Cancer. Cancer Res. 2016;76(8):2301\u201313.","journal-title":"Cancer Res"},{"key":"3280_CR127","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pharmthera.2014.12.003","volume":"149","author":"V Yadav","year":"2015","unstructured":"Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB. Co-targeting BRAF and cyclin dependent kinases 4\/6 for BRAF mutant cancers. Pharmacol Ther. 2015;149:139\u201349.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"3280_CR128","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3892\/ijo.2015.3097","volume":"47","author":"T Mahgoub","year":"2015","unstructured":"Mahgoub T, Eustace AJ, Collins DM, Walsh N, O\u2019Donovan N, Crown J. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma. Int J Oncol. 2015;47(3):900\u20138.","journal-title":"Int J Oncol"},{"issue":"10","key":"3280_CR129","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-15-2931","volume":"76","author":"A Yoshida","year":"2016","unstructured":"Yoshida A, Lee EK, Diehl JA. Induction of therapeutic senescence in Vemurafenib-Resistant melanoma by extended inhibition of CDK4\/6. Cancer Res. 2016;76(10):2990\u20133002.","journal-title":"Cancer Res"},{"issue":"10","key":"3280_CR130","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/ijc.31220","volume":"142","author":"CA Martin","year":"2018","unstructured":"Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, et al. Palbociclib synergizes with BRAF and MEK inhibitors in treatment na\u00efve melanoma but not after the development of BRAF inhibitor resistance. Int J Cancer. 2018;142(10):2139\u201352.","journal-title":"Int J Cancer"},{"issue":"8","key":"3280_CR131","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/nm.2863","volume":"18","author":"A Gembarska","year":"2012","unstructured":"Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012;18(8):1239\u201347.","journal-title":"Nat Med"},{"issue":"10","key":"3280_CR132","doi-asserted-by":"publisher","first-page":"e0185801","DOI":"10.1371\/journal.pone.0185801","volume":"12","author":"G Valianatos","year":"2017","unstructured":"Valianatos G, Valcikova B, Growkova K, Verlande A, Mlcochova J, Radova L, et al. A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein. PLoS ONE. 2017;12(10):e0185801.","journal-title":"PLoS ONE"},{"key":"3280_CR133","doi-asserted-by":"publisher","first-page":"2087204","DOI":"10.1155\/2016\/2087204","volume":"2016","author":"R Thapa","year":"2016","unstructured":"Thapa R, Wilson GD. The importance of CD44 as a stem cell biomarker and therapeutic target in Cancer. Stem Cells Int. 2016;2016:2087204.","journal-title":"Stem Cells Int"},{"issue":"1","key":"3280_CR134","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3280_CR135","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3892\/or.2015.4110","volume":"34","author":"TJ Loh","year":"2015","unstructured":"Loh TJ, Moon H, Cho S, Jang H, Liu YC, Tai H, et al. CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer. Oncol Rep. 2015;34(3):1231\u20138.","journal-title":"Oncol Rep"},{"issue":"9","key":"3280_CR136","first-page":"1831","volume":"55","author":"CJ Rall","year":"1995","unstructured":"Rall CJ, Rustgi AK. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res. 1995;55(9):1831\u20135.","journal-title":"Cancer Res"},{"issue":"2","key":"3280_CR137","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4103\/jomfp.JOMFP_246_18","volume":"23","author":"MN Mishra","year":"2019","unstructured":"Mishra MN, Chandavarkar V, Sharma R, Bhargava D. Structure, function and role of CD44 in neoplasia. J Oral Maxillofac Pathol. 2019;23(2):267\u201372.","journal-title":"J Oral Maxillofac Pathol"},{"issue":"5","key":"3280_CR138","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/omi.2021.0025","volume":"25","author":"K Dzobo","year":"2021","unstructured":"Dzobo K, Sinkala M. Cancer stem cell marker CD44 plays multiple key roles in human cancers: Immune Suppression\/Evasion, Drug Resistance, epithelial-mesenchymal transition, and Metastasis. OMICS. 2021;25(5):313\u201332.","journal-title":"OMICS"},{"issue":"38","key":"3280_CR139","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1038\/onc.2016.67","volume":"35","author":"P Zhang","year":"2016","unstructured":"Zhang P, Feng S, Liu G, Wang H, Fu A, Zhu H, et al. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation. Oncogene. 2016;35(38):5056\u201369.","journal-title":"Oncogene"},{"issue":"7356","key":"3280_CR140","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nature10171","volume":"475","author":"CD Mackereth","year":"2011","unstructured":"Mackereth CD, Madl T, Bonnal S, Simon B, Zanier K, Gasch A, et al. Multi-domain conformational selection underlies pre-mRNA splicing regulation by U2AF. Nature. 2011;475(7356):408\u201311.","journal-title":"Nature"},{"issue":"4","key":"3280_CR141","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/cam4.4506","volume":"11","author":"HP Weitzenb\u00f6ck","year":"2022","unstructured":"Weitzenb\u00f6ck HP, Gschwendtner A, Wiesner C, Depke M, Schmidt F, Trautinger F, et al. Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment. Cancer Med. 2022;11(4):956\u201367.","journal-title":"Cancer Med"},{"issue":"38","key":"3280_CR142","doi-asserted-by":"publisher","first-page":"32006","DOI":"10.1021\/acsami.8b12393","volume":"10","author":"Y Qian","year":"2018","unstructured":"Qian Y, Liang X, Yang J, Zhao C, Nie W, Liu L, et al. Hyaluronan reduces Cationic Liposome-Induced toxicity and enhances the Antitumor Effect of targeted gene delivery in mice. ACS Appl Mater Interfaces. 2018;10(38):32006\u201316.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"12","key":"3280_CR143","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/biom11121850","volume":"11","author":"M Hassn Mesrati","year":"2021","unstructured":"Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of Cancer Progression. Biomolecules. 2021;11(12):1850.","journal-title":"Biomolecules"},{"issue":"5","key":"3280_CR144","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.tig.2011.02.004","volume":"27","author":"SM Hammond","year":"2011","unstructured":"Hammond SM, Wood MJA. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 2011;27(5):196\u2013205.","journal-title":"Trends Genet"},{"issue":"9","key":"3280_CR145","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nm.4165","volume":"22","author":"SCW Lee","year":"2016","unstructured":"Lee SCW, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22(9):976\u201386.","journal-title":"Nat Med"},{"issue":"22","key":"3280_CR146","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.1093\/nar\/gkq731","volume":"38","author":"JA Bauman","year":"2010","unstructured":"Bauman JA, Li SD, Yang A, Huang L, Kole R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 2010;38(22):8348\u201356.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3280_CR147","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/cancers14071726","volume":"14","author":"A Bernard","year":"2022","unstructured":"Bernard A, Boidot R, V\u00e9gran F. Alternative splicing in Cancer and Immune cells. Cancers (Basel). 2022;14(7):1726.","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03280-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-024-03280-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03280-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T18:04:12Z","timestamp":1710353052000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-024-03280-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,10]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3280"],"URL":"https:\/\/doi.org\/10.1186\/s12935-024-03280-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,10]]},"assertion":[{"value":"29 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}